{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:34Z","timestamp":1792108834969,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ccm.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:35:06Z","timestamp":1621553706000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"42","author":[{"given":"Margaret L.","family":"Salisbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/rccm.201903-0614PP","article-title":"Comprehensive supportive care for patients with fibrosing interstitial lung disease","volume":"200","author":"Wijsenbeek","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2021.03.004_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1479973119858961","article-title":"Idiopathic pulmonary fibrosis: educational needs of health-care providers, patients, and caregivers","volume":"16","author":"Ramadurai","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1183\/13993003.01566-2015","article-title":"The lived experience with idiopathic pulmonary fibrosis: a qualitative study","volume":"47","author":"Overgaard","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib5","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.ccm.2021.03.004_bib7","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ccm.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"issue":"9779","key":"10.1016\/j.ccm.2021.03.004_bib10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ccm.2021.03.004_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"1800230","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000495046","article-title":"Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events","volume":"97","author":"Bendstrup","year":"2019","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01797-2018","article-title":"Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials","volume":"54","author":"Noth","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"e000323","DOI":"10.1136\/bmjresp-2018-000323","article-title":"Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials","volume":"5","author":"Nathan","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12325-014-0112-1","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events","volume":"31","author":"Costabel","year":"2014","journal-title":"Adv Ther"},{"issue":"146","key":"10.1016\/j.ccm.2021.03.004_bib19","doi-asserted-by":"crossref","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","article-title":"Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries","volume":"17","author":"Maher","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"11","key":"10.1016\/j.ccm.2021.03.004_bib21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1513\/AnnalsATS.201912-880OC","article-title":"Antifibrotic drug use in patients with IPF: data from the IPF-PRO registry","volume":"17","author":"Salisbury","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"1801655","DOI":"10.1183\/13993003.01655-2018","article-title":"Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials","volume":"53","author":"Cottin","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12931-019-1021-2","article-title":"Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis","volume":"20","author":"Costabel","year":"2019","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib25","doi-asserted-by":"crossref","first-page":"1900399","DOI":"10.1183\/13993003.00399-2019","article-title":"Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis","volume":"54","author":"Glassberg","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A\u00a0multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS(R) trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib29","doi-asserted-by":"crossref","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40248-018-0126-7","article-title":"Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries","volume":"13","author":"Pesonen","year":"2018","journal-title":"Multidiscip Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12931-020-1315-4","article-title":"Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry","volume":"21","author":"Holtze","year":"2020","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000490667","article-title":"Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views","volume":"96","author":"Maher","year":"2018","journal-title":"Respiration"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1513\/AnnalsATS.201810-720RL","article-title":"Pirfenidone treatment in individuals with idiopathic pulmonary fibrosis: impact of timing of treatment initiation","volume":"16","author":"Maher","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00049-2018","article-title":"Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice","volume":"4","author":"Fletcher","year":"2018","journal-title":"ERJ Open Res"},{"issue":"19","key":"10.1016\/j.ccm.2021.03.004_bib35","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccm.2021.03.004_bib36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model","volume":"189","author":"Selman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.ccm.2021.03.004_bib38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1084\/jem.20162152","article-title":"Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span","volume":"214","author":"Misharin","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.ccm.2021.03.004_bib40","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.2013.5827","article-title":"Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis","volume":"309","author":"Peljto","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib41","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"21","key":"10.1016\/j.ccm.2021.03.004_bib42","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.pupt.2013.01.008","article-title":"Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis","volume":"26","author":"Dillingh","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ccm.2021.03.004_bib44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S2213-2600(19)30172-9","article-title":"Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study","volume":"7","author":"Raghu","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"22","key":"10.1016\/j.ccm.2021.03.004_bib45","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial","volume":"319","author":"Raghu","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00850-2015","article-title":"Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy","volume":"47","author":"van den Blink","year":"2016","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.ccm.2021.03.004_bib47","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Martinez","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.03.004_bib48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","article-title":"Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"4","author":"Behr","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib50","doi-asserted-by":"crossref","first-page":"2000348","DOI":"10.1183\/13993003.00348-2020","article-title":"Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial","volume":"57","author":"Sakamoto","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.201509-1753OC","article-title":"Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities","volume":"194","author":"Ho","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2021.03.004_bib53","unstructured":"Mackinnon A, Nicol L, Walker J, et\u00a0al. TD139, A Novel Inhaled Galectin-3 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from the First in (IPF) Patients Study. American Journal of Respiratory and Critical Care Medicine 2020;201:A7560."},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib54","doi-asserted-by":"crossref","first-page":"1802111","DOI":"10.1183\/13993003.02111-2018","article-title":"Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end","volume":"52","author":"Wijsenbeek","year":"2018","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2021.03.004_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib57","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib58","doi-asserted-by":"crossref","first-page":"1800663","DOI":"10.1183\/13993003.00663-2018","article-title":"Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis","volume":"53","author":"Khalil","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib60","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2021.03.004_bib61","unstructured":"Mouded M, Culver DA, Hamblin MJ, et\u00a0al. Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of BG00011 (Formerly STX-100) in Patients with Idiopathic Pulmonary Fibrosis (IPF). In: D14. ILD: CLINICAL RESEARCH.A7785-A7785."},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib62","doi-asserted-by":"crossref","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A\u00a0randomised, placebo-controlled study of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201607-1525OC","article-title":"Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis","volume":"196","author":"Huang","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.03.004_bib64","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1164\/rccm.201607-1408OC","article-title":"Host-microbial interactions in idiopathic pulmonary fibrosis","volume":"195","author":"Molyneaux","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib65","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S2213-2600(14)70069-4","article-title":"Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study","volume":"2","author":"Han","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.ccm.2021.03.004_bib66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","article-title":"The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis","volume":"190","author":"Molyneaux","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2021.03.004_bib67","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201809-1650OC","article-title":"Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis","volume":"199","author":"O'Dwyer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/thoraxjnl-2012-202403","article-title":"Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial","volume":"68","author":"Shulgina","year":"2013","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib69","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.03.004_bib70","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2021.03.004_bib71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2213-2600(18)30301-1","article-title":"Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial","volume":"6","author":"Raghu","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/thoraxjnl-2018-212102","article-title":"Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis","volume":"74","author":"Dutta","year":"2019","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib73","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.201607-1385OC","article-title":"Idiopathic pulmonary fibrosis: the association between the adaptive multiple features method and fibrosis outcomes","volume":"195","author":"Salisbury","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib74","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1378\/chest.15-0530","article-title":"Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline","volume":"149","author":"Salisbury","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12890-016-0308-z","article-title":"Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series","volume":"16","author":"Delanote","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ccm.2021.03.004_bib76","article-title":"Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy","author":"Leuschner","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib77","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/resp.12989","article-title":"Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry","volume":"22","author":"Glaspole","year":"2017","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/ajrccm.155.1.9001319","article-title":"Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis","volume":"155","author":"Baumgartner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib79","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/thoraxjnl-2014-206420","article-title":"Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin","volume":"70","author":"Knippenberg","year":"2015","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib80","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.chest.2019.05.028","article-title":"Interstitial, diffuse lung disease network steering C. Preoperative evaluation of patients with interstitial lung disease","volume":"156","author":"Patel","year":"2019","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib81","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.ccm.2021.03.004_bib82","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S2213-2600(14)70226-7","article-title":"An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial","volume":"2","author":"Higginson","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.03.004_bib83","first-page":"1567","article-title":"Short-term effects of comprehensive pulmonary rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a randomized controlled trial","volume":"9","author":"Jarosch","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib84","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00045-2019","article-title":"Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias","volume":"5","author":"Wallaert","year":"2019","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib85","doi-asserted-by":"crossref","first-page":"1900421","DOI":"10.1183\/13993003.00421-2019","article-title":"Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey","volume":"54","author":"Lim","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2021.03.004_bib86","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.ccm.2021.03.004_bib87","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/resp.13829","article-title":"Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation","volume":"25","author":"Arizono","year":"2020","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chest.2020.01.049","article-title":"Ambulatory oxygen in fibrotic interstitial lung disease: a pilot, randomized, triple-blinded, sham-controlled trial","volume":"158","author":"Khor","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib89","doi-asserted-by":"crossref","first-page":"1801278","DOI":"10.1183\/13993003.01278-2018","article-title":"Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study","volume":"52","author":"Bajwah","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1191\/0269216305pm998oa","article-title":"Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis","volume":"19","author":"Allen","year":"2005","journal-title":"Palliat Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.03.004_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12931-020-01452-7","article-title":"Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial","volume":"21","author":"Kronborg-White","year":"2020","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.ccm.2021.03.004_bib92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/jpm.2016.0432","article-title":"Low-dose morphine for dyspnea in terminally ill patients with idiopathic interstitial pneumonias","volume":"20","author":"Matsuda","year":"2017","journal-title":"J\u00a0Palliat Med"},{"issue":"7","key":"10.1016\/j.ccm.2021.03.004_bib93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2169\/internalmedicine.55.5362","article-title":"Continuous intravenous morphine infusion for severe dyspnea in terminally ill interstitial pneumonia patients","volume":"55","author":"Takeyasu","year":"2016","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.ccm.2021.03.004_bib94","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/SPC.0000000000000447","article-title":"Cough, an unresolved problem in interstitial lung diseases","volume":"13","author":"van Manen","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"issue":"4","key":"10.1016\/j.ccm.2021.03.004_bib95","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","article-title":"Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report","volume":"154","author":"Birring","year":"2018","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2021.03.004_bib96","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jaip.2019.04.027","article-title":"Cough: new pharmacology","volume":"7","author":"Smith","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.ccm.2021.03.004_bib97","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/thoraxjnl-2014-206583","article-title":"Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention","volume":"70","author":"Bajwah","year":"2015","journal-title":"Thorax"},{"issue":"153","key":"10.1016\/j.ccm.2021.03.004_bib98","doi-asserted-by":"crossref","first-page":"190044","DOI":"10.1183\/16000617.0044-2019","article-title":"Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue","volume":"28","author":"Caminati","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2021.03.004_bib99","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.01.008","article-title":"Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis","volume":"148","author":"Sheth","year":"2019","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.03.004_bib100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jpainsymman.2017.10.016","article-title":"Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths","volume":"55","author":"Kalluri","year":"2018","journal-title":"J\u00a0Pain Symptom Manage"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:59:34Z","timestamp":1759453174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523121000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0272523121000319"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2021.03.004","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}